Press Releases Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
5.2 ^USD	+0.58%		-7.64%	-48.67%

May. 30	Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating	MT
May. 14	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June	May. 14	GL
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June	May. 14	AQ
Editas Medicine Preclinical Data Highlights Advancement Of In Vivo Gene Editing Medicine Technologies at The American Society Of Gene And Cell Therapy Annual Meeting	May. 13	AQ
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting	May. 10	GL
Editas: Q1 Earnings Snapshot	May. 08	AQ
Editas Medicine Announces First Quarter 2024 Results and Business Updates	May. 08	GL
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events	May. 02	GL
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	GL
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	Apr. 22	GL
Editas Medicine : April 2024 Corporate Presentation	Apr. 11	PU
Editas Medicine : Corporate Effectiveness Report April 2024	Apr. 11	PU
Editas: Q4 Earnings Snapshot	Feb. 28	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	Feb. 28	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	Feb. 28	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	Feb. 21	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	Feb. 21	AQ
Editas Medicine to Participate in Upcoming Investor Conferences	Jan. 31	GL
Editas Medicine to Participate in Upcoming Investor Conferences	Jan. 31	AQ
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	Jan. 08	GL
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	Jan. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Press Releases

Filters